| Discovery Labs to Provide an Update on FDA Review of Surfaxin ND |
| Date: Tuesday, February 01, 2005 |
| Time: 08:45 am (Eastern) |
|
The previously-recorded webcasts and the information contained in the presentations included in this section are provided as a service to investors and other interested parties. While such information was accurate, in all material respects, at the time of its original presentation, the Company has undertaken no obligation whatsoever to update, correct or otherwise modify any of the information contained in these presentations. Accordingly, YOU SHOULD NOT RELY ON THE ACCURACY OF ANY OF THE STATEMENTS IN THE PRESENTATION OR ANY OTHER INFORMATION CONTAINED IN THIS SECTION. Furthermore, these presentations may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, at the time they were made, were based on then-current expectations of future events. If any of those underlying assumptions prove or have proven to be inaccurate or unknown or if risks or uncertainties materialize or have materialized, actual results could vary or already may have varied materially from the Company's expectations and projections in these presentations. These risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. Actual results could vary materially from those described as a result of a number of factors, including those set forth in Discovery’s Annual Report on Form 10-KSB and any subsequent SEC filings, as they may have been amended.
The Company assumes no obligation to update any forward-looking statements or any other information contained herein as a result of new information or future events or developments.
This presentation does not constitute an offer to purchase any securities, nor a solicitation of a proxy, consent or agent designation with respect to a meeting of the Company’s stockholders.
|
